• 1
    Montserrat E. CLL therapy: progress at last. Blood 2005; 105:23.
  • 2
    Spaner D. Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. J Leukoc Biol 2004; 76:33851.
  • 3
    Tomic J, White D, Shi Y et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006; 176:383039.
  • 4
    Herr I, Debatin K. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98:260314.
  • 5
    Dowlati A, Lazarus H, Hartman P et al. Phase I study of bryostatin 1 and vincristine in relapsed B-cell malignancies. Clin Cancer Res 2003; 9:592935.
  • 6
    Raphael B, Andersen JW, Silber R et al. Comparison of chlorambucil and prednisone versus CVP as initial treatment for CLL. J Clin Oncol 1991; 9:7706.
  • 7
    Hammond C, Shi Y, Mena J et al. Effect of serum and antioxidants on the immunogenicity of PKC-activated CLL cells. J Immunother 2005; 28:2839.
  • 8
    Spaner D, Shi Y, Mena J et al. Immunomodulatory effects of TLR7 activation on CLL cells. Leukemia 2006; 20:28695.
  • 9
    Shanafelt TD, Geyer SM, Kay NE. CLL prognosis at diagnosis. Blood 2004; 103:120210.
  • 10
    Stone J, Stang S, Zheng Y et al. Synthetic bryostatin analogues activate the RasGRP1 signaling pathway. J Med Chem 2004; 47:663844.
  • 11
    Bueno C, Rodriguez-Caballero A, Garcia-Montero A et al. A new method for detecting TNF-α-secreting cells. J Immunol Methods 2003; 264:7787.
  • 12
    Vilpo J, Koski T, Vilpo L. Selective vincristine toxicity against CLL cells in vitro. Eur J Haematol 2000; 65:3708.
  • 13
    Spaner DE, Hammond C, Mena J, Shi Y. Effect of IL-2Rβ-binding cytokines on costimulatory properties of CLL cells: implications for immunotherapy. Br J Haematol 2004; 127:53142.
  • 14
    O'Connor T. Phorbol ester-induced loss of colchicine ultrasensitivity in CLL cells. Leuk Res 1985; 9:88595.
  • 15
    Cassimeris L. The stathmin family of microtubule destabilizers. Curr Opin Cell Biol 2002; 14:1824.
  • 16
    Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:1122.
  • 17
    Manning A, Davis R. Targeting JNK for therapeutic benefit. Nat Rev Drug Discov 2003; 2:55465.
  • 18
    Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3:83144.
  • 19
    Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids. Science 1995; 270:28690.
  • 20
    Arbuzova A, Schmitz A, Vergeres G. MARCKS proteins. Biochem J 2002; 362:112.
  • 21
    Hofmann J. Potential for PKC isoenzyme-specific modulation. FASEB J 1997; 11:64969.
  • 22
    Ringshausen I, Schneller F, Bogner C et al. Constitutively activated PI3K is involved in the defect of apoptosis in B-CLL. Blood 2002; 100:37418.
  • 23
    Jordan M, Wilson L. Microtubules as targets for anticancer drugs. Nat Rev Cancer 2004; 4:25365.
  • 24
    Tesniere A, Apetoh L, Ghiringhelli F et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20:50411.
  • 25
    Kyriakis J, Avruch J. Stress activated MAPK signaling pathways. Physiol Rev 2001; 81:80769.
  • 26
    Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 2008; 57:138190.
  • 27
    Zhao C, Morgan M, Haeryfar SM, Blay J, Hoskin DW. Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific CTLs induced with anti-CD3 antibody. Cancer Immunol Immunother 2003; 52:18593.
  • 28
    Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27:624551.
  • 29
    Kawai T, Akira S. Pathogen recognition with TLRs. Curr Opin Immunol 2005; 17:33844.
  • 30
    Berchtold S, Muhl-Zurbes P, Maczek E et al. Cloning and characterization of the promoter region of the human CD83 gene. Immunobiology 2002; 205:23146.
  • 31
    Russwurm S, Bohm KJ, Muhlig P et al. LPS induces distinct alterations in the microtubule cytoskeleton of monocytes. Cell Biol Toxicol 2000; 16:33946.